Clal Insurance’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-800,000
Closed -$35.5M 214
2024
Q3
$35.5M Sell
800,000
-100,000
-11% -$4.28M 0.31% 55
2024
Q2
$35.8M Hold
900,000
0.37% 48
2024
Q1
$38.8M Hold
900,000
0.44% 55
2023
Q4
$37.5M Hold
900,000
0.49% 52
2023
Q3
$35.8M Sell
900,000
-400,000
-31% -$16.9M 0.5% 51
2023
Q2
$53.3M Buy
+1,300,000
New +$53.7M 0.64% 42

Other funds holding XPH

Clal Insurance's XPH Position: Q4 2024 in Review

Clal Insurance sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2024, closing a stake of 800,000 shares — an estimated $35.5M sold.

Clal Insurance first reported a position in XPH in Q2 2023 and held it in 6 quarters. The position peaked at $53.3M in Q2 2023. 73 funds tracked by Wall St. Rank hold XPH as of Q4 2024.

  • Clal Insurance reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2024 after selling out during the quarter.
  • Clal Insurance sold 800,000 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2024, an estimated $35.5M.
  • Clal Insurance first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2023 and held it in 6 quarters.
  • Clal Insurance's State Street SPDR S&P Pharmaceuticals ETF position peaked at $53.3M in Q2 2023.
  • 73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2024.

Based on Clal Insurance's 13F filing for Q4 2024, filed 6 Feb 2025.